CRC Research Update

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

  • Traditional Risk Factors Not Linked to Early-Onset CRC Rise

    A national cohort study using the All of Us Research Program found no significant association between traditional environmental risk factors or established genetic variants and the rising incidence of colorectal cancer in adults under age 50. (Diseases of the Colon & Rectum)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

  • Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC

    A multicenter real-world study from four Chinese hospitals evaluated long-term outcomes of a watch-and-wait strategy in stage II/III dMMR/MSI-H colorectal cancer patients who achieved endoscopic complete response after neoadjuvant anti-PD-1 monotherapy. (Frontiers in Immunology)

  • KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed

    A review article discusses how KRAS G12C mutations account for 3% to 4% of metastatic colorectal cancer cases and explains why combined KRAS G12C and EGFR inhibition may be more effective than monotherapy. (Journal of Gastrointestinal Cancer)

Today's research highlights advances in targeted therapy for specific genetic subtypes and new insights into early-onset disease. As always, discuss any questions about these findings with your care team.